|  |
| --- |
| **Chain length impact on the retro Diels-Alder mediated release of gemcitabine****from hybrid nanoparticles towards pancreatic cancer therapy** |
| Adeolu Oluwasanmi1, Sarah Lindsay2, Anthony Curtis3, Yvonne Perrie2, Clare Hoskins1 |
| 1Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, G1 1RD,UK2Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde,Glasgow, G4 0RE, UK3 School of Pharmacy and Bioengineering, Keele University, Keele, ST5 5BG |
| **Background:** Pancreatic cancer, also known as pancreatic ductal adenocarcinoma (PDAC) is the deadliest type of malignant carcinoma with a 10-year survival rate of only 5%. Disproportionately, it is the 5th most common cause of cancer related death in the UK, while being the 10% most common type of cancer, demonstrating its abysmal survival rate. A previous study investigated the design and synthesis of a novel drug delivery formulation, wherein gemcitabine was conjugated to the surface of gold coated iron oxide nanoparticles (Au-IONP’s) via a 4-carbon thermally labile Diels-Alder based linker (TTLD4). Overall, with the aid of this Diels-Alder linker, the formulation was 56% more effective at tumor retardation in pancreatic models than gemcitabine alone. This study’s objective is to investigate whether the alkyl chain length of the Diels-Alder influences temperature of activation of drug release.  |
| **Methods:** Synthesis of structural analogues of these linkers, was achieved by changing the 4-maleimidobutyric acid, with 3 and 6-length analogues via the EDC/NHS coupling reaction. A 5mL suspension of 5mg/mL drug-linker with 1mg/mL Au-IONP’s (based on Fe conc) was stirred at room temperature for 2h, to form a 5:1 ratio of drug-linker to Au-IONP’s. The drug conjugated Au-IONP’s were magnetically separated, with the supernatant analyzed using high performance liquid chromatography (HPLC). The three formulations were suspended within dialysis membranes at room temperature, 37 and 45 ˚C to determine drug release over time. |
| **Results:** Heat-mediated release of gemcitabine at 45 ˚C over 180 min from these formulations was confirmed to be based on linker length, which was 94%, 76% and 45% for TTLD3, TTLD4 and TTLD6, respectively. Drug loading of the Diels-Alder linkers in a 5:1 Drug/Au-IONP w/w ratio appears to favor those containing an even number of carbons TTLD4 (76%) & TTLD6 (57%) over TTLD3 (25%), possibly due to the linker likely being positioned perpendicular to the Au-IONP surface because of the 120˚ C-C bond. |
| **Conclusions:** The differences in the release of gemcitabine, based on variations in TTLD-(Au-IONP) linker length offer additional opportunities to further control the overall retro Diels-Alder mediated release of gemcitabine from Au-IONP surfaces. This includes the possibility of generating TTLD-(Au-IONP) formulations comprised of a blend of different TTLD linkers to fine tune the overall rate of retro Diels-Alder mediated drug release. |